FORM **NAMCS-CCS** (11-30-2005)

NATIONAL AMBULATORY MEDICAL CARE SURVEY

U.S. DEPARTMENT OF COMMERCE
Economics and Statistics Administration
U.S. CENSUS BUREAU
ACTING AS DATA COLLECTION AGENT FOR THE
U.S. Department of Health and Human Services
Centers for Disease Control and Prevention
National Center for Health Statistics

CERVICAL CANCER SCREENING SUPPLEMENT

NOTICE – Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to: CDC/ATSDR Reports Clearance Officer; 1600 Clifton Road, MS E-11, Atlanta, GA 30333, ATTN: PRA(0920-0234).

Assurance of Confidentiality – All information which would permit identification of an individual, a practice, or an establishment will be held confidential, will be used by persons engaged in and for the purpose of the survey and will not be disclosed or released to other persons or used for any other purpose without the consent of the individual or the establishment in accordance with section 308(d) of the Public Health Service Act (42 USC 242m).

without the consent of the individual or the establishment in accordance with section 308(d) of the Public Health Service Act (42 USC 242m).											
BACKGROUND INFORMATION											
0010	A. Provider's name	0015		Provider telephon			Number				
0020	Provider's specialty (Mark (X) only ONE.) 1 General/Family 2 Internal 3 OB/ 4 CHC Mid-leve Practice Medicine GYN Provider	0025	D. Provider's serial number								
0030	E. Practice contact name	0035	F.	Practice contact telephor		a code	Number				
0040	G. Census contact name	0045	н.	Census contact telephor		a code	Number				
INT	This year the Centers for Disease Control and Prevention is conducting a special survey on cervical cancer screening performed in community health centers and private office settings. Please answer the following questions. We appreciate your time on this important public health concern.										
You have the option to complete this questionnaire on the Internet. Go to www.cdc.gov/namcs , select Cervical Cancer Supplement, enter the User ID and Password displayed, and follow the instructions. Password											
						Mark (X) the interval for routine screening.					
Which of the following methods does your practice use to scr patients for cervical cancer? (Mark (X) all that apply.)				 -	Annually	Every 2 years		More than 3 years	No routine interval recom- mended		
	Conventional Pap test (Definition – Smear spread on glass slide and fixed) 1 Yes – How often does you screen women using spread on glass slide and fixed	ng this	g this method? →		1	2	3	4	5		
	Liquid-based cytology (Definition – Specimen suspended in liquid solution) 1 Yes – How often does you screen women using screen women using 2 No 3 Unknown 2 No 3 Unknown	ng this	meth	routinely nod? →	1	2	3 🗆	4	5		
c.	Other – Specify _₹			I							
5005	0065 1 ☐ Yes – How often does yo screen women usii 2 ☐ No 3 ☐ Unknown	our prac ng this	ctice meth	routinely nod? → 	1	2	3 🗆	4	5 🗆		

2.	Does your practice perform colposcopy?						
0050	1□Yes						
	2 □ No 3 □ Unknown						
2-	December 2019 and an exploration of collect the Human Deciller 2019 (LIDV) DNA test?						
	Does your practice ever order or collect the Human Papillomavirus (HPV) DNA test?						
0070	1 ☐ Yes – Go to item 3b 2 ☐ No – SKIP to item 3c						
	3 Not aware of HPV DNA test SKIP to item 7 on page 4						
	4 Unknown						
b.	Which of the following HPV DNA tests are ordered or collected in your practice? (Mark (X) all that apply.)						
	1 ☐ High risk (HR) HPV DNA test						
0075	a Low rick (LD) HDV DNA toot						
	3 Not aware there was a high risk or low risk HPV DNA test						
	4 Unknown						
	Why is the HPV DNA test not ordered or collected in your practice?						
C.	(Mark (X) all that apply.)						
0800	1 ☐ My practice does not see the types of patients for whom the HPV DNA test is indicated.						
	₂ My practice uses other tests, procedures, or examination methods to manage patients for whom the HPV DNA						
	test is indicated.						
	3 ☐ My patients in my practice have timely access to colposcopy.						
	4 ☐ Assessing patients' HPV infection status is not a priority at my practice.						
	5 ☐ The labs affiliated with my practice do not offer the HPV DNA test.						
	6 ☐ The health plans or health systems affiliated with my practice do not recommend the HPV DNA test.						
	7 ☐ The HPV DNA test is not a reimbursed or covered service for most patients in my practice.						
	8 ☐ Discussing cervical cancer screening in the context of an STD is avoided in my practice.						
	9 ☐ Notifying or counseling patients about positive HPV DNA test results would take too much time.						
	10 Notifying or counseling patients about positive HPV DNA test results might make clinicians in my practice feel uncomfortable.						
	11 ☐ Notifying or counseling patients about positive HPV DNA test results might make patients in my practice feel uncomfortable, angry, or upset.						
	SKIP to item 7 on page 4.						
4a.	If a patient's screening Pap test result is borderline or abnormal, does your practice routinely order an HPV DNA test to be performed on that sample (commonly called reflex HPV DNA testing)? (An HPV DNA test may be run on the same liquid-based medium as the screening Pap test or an HPV DNA test specimen may be collected at the same time as the conventional Pap test.)						
0085	1 ☐ Yes – Go to item 4b						
	2 No CKIR to item 55 on your 0						
	3 ☐ Unknown } SKIP to item 5a on page 3						

Page 2 FORM NAMCS-CCS (11-30-2005)

4b.	For which abnormal or borderline Pap test result would your practice order or collect an HPV DNA test? (Mark (X) all that apply.)
0090	□ ASC-US (atypical squamous cells of undetermined significance) □ ASC-H (atypical squamous cells of undetermined significance — cannot exclude high-grade intraepithelial lesion) □ LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasia/CIN1) □ HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ) □ AGC (atypical glandular cells)
c.	For which patients does your practice usually order reflex HPV DNA testing? (Mark (X) all that apply.)
0095	1 Women under 30 years old 2 Women 30 years old and over 3 Other − Specify ✓
5010	
	Does your practice routinely recall patients to come back for a second sample collection for an HPV DNA test if their screening Pap test is abnormal or borderline (recall testing)? 1 Yes - Go to item 5b 2 No 3 Unknown SKIP to item 6a
	For which abnormal or borderline Pap test result would your practice recall a patient for an HPV DNA test? (Mark (X) all that apply.)
0105	ASC-US (atypical squamous cells of undetermined significance) □ ASC-H (atypical squamous cells of undetermined significance − cannot exclude high-grade intraepithelial lesion) □ LSIL (low-grade squamous intraepithelial lesion, encompassing mild dysplasia/CIN1) □ HSIL (high-grade squamous intraepithelial lesion, moderate dysplasia/CIN2, severe dysplasia/CIN3, and carcinoma in situ) □ AGC (atypical glandular cells)
6a.	Does your practice routinely order or collect an HPV DNA test at the same time as the Pap test as part of routine cervical cancer screening (sometimes called adjunct HPV testing or cotesting)?
0110	1 ☐ Yes – Go to item 6b 2 ☐ No 3 ☐ Unknown SKIP to item 7 on page 4
b.	For which patients does your practice routinely order or collect an HPV DNA test along with the Pap test? (Mark (X) all that apply.) 1 Women under 30 years old 2 Women 30 years old and over 3 Women who request the test for cervical cancer screening 4 Women who request the test to check their HPV infection status 5 Other – Specify
5015	

FORM NAMCS-CCS (11-30-2005)

7. If your practice were to see a woman between 30 and 60 years of age with a CURRENT NORMAL screening Pap test result, when would this clinic (given the following prior Pap test history and CURRENT HPV DNA test result) routinely recommend that she get her next Pap test?										
			(For each of the following scenarios, mark (X) only ONE for each row.)							
Prior Pap test results in past 5 years (excluding current normal results) Current HPV DNA test results		No follow-up needed	Less than 6 months	6 months to less than 1 year	1 year	2 years	3 years or more	Have no experience with this type of patient or test		
0120 (a)	Two Consecutive Normal Pap tests	Has not had test	1	2	з 🗌	4 🗌	5 🗌	6	7	
0125 (b)	Two Consecutive Normal Pap tests	 Negative 	1 🗆	2	3 🗆	4 🗆	5 🗌	6	7 🗆	
0130 (c)	Two Consecutive Normal Pap tests	 Positive 	1	2	3 🗆	4	5	6	7	
0135 (d)	Has not had a Pap test	 Negative 	1	2	з 🗆	4 🗆	5 🗌	6	7 🗆	
0140 (e)	Has not had a Pap test	 Positive	1	2	3 🗆	4	5 🗌	6	7	
0145 (f)	Abnormal Pap test	 Negative 	1 🗆	2	3 🗆	4 🗆	5	6	7	
0150 (g)	Abnormal Pap test	Positive	1	2	3 🗆	4	5 🗌	6	7	
8. The Centers for Disease Control and Prevention (CDC) funds state health departments to provide breast and cervical cancer screening services to low income women through the National Breast and Cervical Cancer Early Detection Program (Title XV). The state health departments contract out the screening services to physicians and other health care providers. Is your practice currently participating in this state or national screening program? 1 Yes 1 Yes 2 No 3 Unknown										
0160 1	(Mark (X) only ONE.)									

CLOSING STATEMENT

Thank you for completing this special survey. We appreciate your time and cooperation.